RESPECTIVE CONTRIBUTIONS OF THE PARTIES Sample Clauses

RESPECTIVE CONTRIBUTIONS OF THE PARTIES. A. Joint Responsibilities
Sample 1Sample 2Sample 3See All (11)
AutoNDA by SimpleDocs
RESPECTIVE CONTRIBUTIONS OF THE PARTIES. COLLABORATOR RESPONSIBILITIES Protarga's contributions to the collaborative research and development of the agent will include the following: o Protarga has an active research program in fatty acid conjugate chemistry and will contribute expertise towards this collaboration; o Protarga will conjugate agents supplied by the Pharmaceutical Resources Branch of the DTP with the appropriate fatty acid using their proprietary Targaceutical-TM- Technology; o Protarga will characterize the initial purity and stability of the Targaceutical-TM- Conjugates; and o Protarga will provide initial supplies of the conjugated drug sufficient for preclinical testing of the Targaceutical-TM- Conjugates. NCI RESPONSIBILITIES NCI's contribution to the collaborative research and development of the compounds will include the following: o NCI, based on their expertise, in conjunction with the CRADA Steering Committee (described below), will select up to twelve agents per month from its repository, to be linked to fatty acids. These agents will exhibit a novel mechanism of action, a need to reduce toxicity or increase efficacy, an appropriate chemical group for conjugation, and the presence of sufficient compound in the NCI repository. The quantity supplied of any agent selected will not exceed 50% of NCI's current inventory; o NCI will supply the agent for all preclinical efficacy toxicology/pharmacology studies set forth under the scope of this CRADA. If there is insufficient compound remaining in the NCI repository to complete these studies it shall be the responsibility of the NCI to resynthesize additional compound, where practicable and feasible; * Confidential treatment requested: material has been omitted and filed separately with the Commission. o NCI will collaborate solely with Protarga for the development of Targaceutical-TM- Conjugates based on Protarga's proprietary technology for attaching anti-neoplastic molecules to fatty acids for therapeutic effectiveness in cancer; and o NCI will evaluate each of the active studies as they progress to ensure that the appropriate questions are being addressed and to ensure that the studies are modified as required based on the developing data. If there are Targaceutical-TM- Conjugates emerging from these studies which exhibit enough initial IN VIVO and IN VITRO activity as to warrant further preclinical development, the results of the studies will be presented to the NCI DN for approval to conduct studies at the DNIIA level of pr...
Sample 1
RESPECTIVE CONTRIBUTIONS OF THE PARTIES. Acer Therapeutics has defined a target product profile for this clinical opportunity and are generating data packages for submission to FDA under an Emergency Use Application (EUA) to support human clinical testing. NCATS has completed a literature review of clinical experience with emetine use, as well as important artifacts including previous drug product labels, and a drug master file that it intends to share. NCATS also has access to considerable physical material (50g) of emetine to support further nonclinical safety and efficacy studies as needed.
Sample 1

Related to RESPECTIVE CONTRIBUTIONS OF THE PARTIES

  • Capital Contributions of the Partners (a) The Partners have made the Capital Contributions as set forth in Exhibit A.

  • Actions of the Parties Except as otherwise provided in this Agreement, whenever this Agreement calls for or permits a party's approval, consent, or waiver, the written approval, consent, or waiver of the City Manager or the Successor Agency Executive Director shall constitute the approval, consent, or waiver of the respective parties, without further authorization required from the governing board of the party; provided, however, that the person vested with such authority may seek such further advice or authorization from the applicable governing board when he/she deems it appropriate.

  • Limitations Pertaining to Capital Contributions 5.2.1: Except as otherwise specifically provided in this Agreement, or as otherwise provided by law, no Member shall have the right to withdraw from the Company or to demand or receive a return of his capital without the consent of the Manager. Upon return of any Capital Contributions, no Member shall have the right to receive property other than cash except as may be specifically provided herein.

  • Allocations of Profits and Losses Except as otherwise provided in this Agreement, Profits and Losses (and, to the extent necessary, individual items of income, gain or loss or deduction of the Partnership) shall be allocated in a manner such that the Capital Account of each Partner after giving effect to the Special Allocations set forth in Section 5.05 is, as nearly as possible, equal (proportionately) to (i) the distributions that would be made pursuant to Article IV if the Partnership were dissolved, its affairs wound up and its assets sold for cash equal to their Carrying Value, all Partnership liabilities were satisfied (limited with respect to each non-recourse liability to the Carrying Value of the assets securing such liability) and the net assets of the Partnership were distributed to the Partners pursuant to this Agreement, minus (ii) such Partner’s share of Partnership Minimum Gain and Partner Nonrecourse Debt Minimum Gain, computed immediately prior to the hypothetical sale of assets. For purposes of this Article V, each Unvested Unit shall be treated as a Vested Unit. Notwithstanding the foregoing, the General Partner shall make such adjustments to Capital Accounts as it determines in its sole discretion to be appropriate to ensure allocations are made in accordance with a partner’s interest in the Partnership.

  • Obligations of the Parties 2.1 The Trust shall prepare and be responsible for filing with the Securities and Exchange Commission and any state regulators requiring such filing all shareholder reports, notices, proxy materials (or similar materials such as voting instruction solicitation materials), prospectuses and statements of additional information of the Trust. The Trust shall bear the costs of registration and qualification of its shares, preparation and filing of the documents listed in this Section 2.1 and all taxes to which an issuer is subject on the issuance and transfer of its shares.

  • Distributions and Allocations All distributions of cash or other property (except upon the Company's dissolution, which shall be governed by the applicable provisions of the Act and Article IX hereof) and all allocations of income, profits, and loss shall be made 100% to the Member in accordance with its Membership Interest. All amounts withheld pursuant to the Code or any provisions of state or local tax law with respect to any payment or distribution to the Member from the Company shall be treated as amounts distributed to the Member pursuant to this Section 7.3. Notwithstanding any provision to the contrary contained in this Agreement, the Company shall not be required to make a distribution to the Member on account of its interest in the Company if such distribution would violate Section 18-607 of the Act or any other applicable law.

  • Collections and Allocations (a) The Borrower or the Servicer on behalf of the Borrower shall promptly (but in no event later than two (2) Business Days after the receipt thereof) identify any Collections received by it as being on account of Interest Collections or Principal Collections and deposit all such Interest Collections or Principal Collections received directly by it into the Collection Account. The Servicer on behalf of the Borrower shall make such deposits or payments on the date indicated by wire transfer, in immediately available funds.

  • Conditions to Obligations of the Parties The obligations of the parties hereto to effect the transactions contemplated by this Agreement shall be subject to the satisfaction at the Closing (as defined below) of the following conditions:

  • Conditions to the Obligations of the Parties The obligations of the Parties to consummate the transactions contemplated by this Agreement are subject to the satisfaction or, if permitted by applicable Law, waiver by the Party for whose benefit such condition exists of the following conditions:

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!